S427
Clinical - Gynaecological
ESTRO 2026
patients (38%) received a simultaneous integrated boost, while 2 (15%) received a sequential boost. Boost targets included gross nodal disease in the pelvis, inguinal, para-aortic, or ischial regions (typically to 45 Gy) and residual primary or soft-tissue lesions (cervix, parametria, mesorectum, or external genitalia) escalated up to 60 Gy. All patients experienced improvement in at least one symptom, typically midway through treatment (median dose 29 Gy in 11 fractions). Three patients (23%) proceeded to systemic therapy following HFRT. Treatment completion was high (85%), and acute toxicity was mostly mild (Grade 1–2). Median follow- up was 1.5 months (range 0–6), with 2 patients (15%) followed for more than 3 months; no clinically significant late toxicity was observed. The high compliance and rapid symptom relief suggest that HFRT is a practical, safe, effective and efficient palliative regimen. Conclusion: Moderate HFRT provides safe, rapid palliation for advanced gynecologic malignancies and can enable transition to systemic therapy in resource-limited settings. This approach is feasible, efficient, and particularly valuable in low to middle-income countries contexts where conventional radiotherapy may be challenging to deliver. References: Amjad R. Hypofractionated radiotherapy in gynecologic malignancies—A peek into the upcoming evidence. Cancers (Basel). 2024;16(2):362. doi:10.3390/cancers16020362.Mallum A. A comparative analysis of hypofractionated versus conventional radiotherapy for cervical cancer in a resource-limited setting: a prospective study. Front Oncol. 2025;15:1552346. doi:10.3389/fonc.2025.1552346.Bacorro W. Phase 1/2 trial evaluating the effectiveness and safety of dose-adapted hypofractionated pelvic radiotherapy for advanced cervical cancers ineligible for chemotherapy (HYACINCT). Acta Oncol. 2022;61(6):688–97.
doi:10.1080/0284186X.2022.2048070. PMID:35285405. Keywords: hypofractionated, palliation, gynecology
Digital Poster 1502 Recurrence pattern of Definitive Radiotherapy in Elderly Patients with Locally Advanced Uterine Cervical Cancer Takeshi Fujisawa, Taisuke Sumiya, Takashi Saito, Haruko Numajiri, Harada Masahiko, Masaaki Goto, Takuya Sawada, Keiichiro Baba, Toshiki Ishida, Masatoshi Nakamura, Takashi Iizumi, Kei Nakai, Hideyuki Sakurai Radiation oncology, Tsukuba university hospital, Tsukuba, Japan Purpose/Objective: The standard treatment for locally advanced uterine cervical cancer is definitive chemoradiotherapy, which includes the entire pelvic area. However, elderly patients often receive radiotherapy alone due to poor performance status or renal dysfunction. Although there are a few reports on the clinical outcomes of radiotherapy alone for elderly patients, detailed reports on recurrence patterns are scarce. Therefore, we conducted a retrospective study to evaluate the recurrence in elderly patients with cervical cancer who received definitive radiotherapy (dRT) alone. Material/Methods: We reviewed medical records from March 2013 to October 2024. Eligible patients had pathologically confirmed squamous cell carcinoma, were ≥ 70 years old, and underwent dRT for any reason that they could not have received chemoradiotherapy (CRT). We excluded patients with stages IB1 and IIA1 to assess the cohort of those who are to be treated by CRT. All patients received a total dose of 30-40 Gy of whole pelvic (WP) irradiation, followed by a total accumulated
dose of 50 Gy of central shielding (CS) irradiation. Patients with lymph node
Made with FlippingBook - Share PDF online